Skip to content
stoqly
en

Languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Afya Ltd

AFYA Nasdaq Services-Educational Services Financials FY2017–FY2025

Afya Ltd had $661M of revenue in fiscal 2025, up 7.8% on the year before. Over five years, revenue changed +23.2% a year on average.

Download report 3-page PDF: the company, its results and charts with peers.

Last close Β· Oct 23, 2026

$15.09

1.2%

What Afya Ltd does

AFYA Β· Services-Educational Services

From its latest annual report

No business description yet.

Filing details

Legal name
Afya Ltd
Fiscal year ends
December 31, 2025
Latest annual report
20-F Β· Mar 31, 2026
Accession Β· CIK
0001292814-26-002013 Β· 0001771007

KIRA’s summary AI analyst

Hi! I read Afya Ltd’s latest annual report (fiscal 2025). Here is what stands out:

6 strengths

1.Sales and profit

See section β†’
  • Afya Ltd had $661M of revenue in fiscal 2025, up 7.8% on the year before. Over five years, revenue changed +23.2% a year on average.
  • Its operating margin was 32.8%, up 2.2Β pts: of every 100 in sales, about 33 is left after running the business.
  • Afya Ltd made $135M of net profit in fiscal 2025. From fiscal 2017 to 2025, diluted EPS grew 16.3% a year.

2.Cash and shareholders

See section β†’
  • Free cash flow was $244M in fiscal 2025, 36.9% of revenue.
  • Afya Ltd returned $26.3M to shareholders in fiscal 2025, 11% of free cash flow. The diluted share count rose 0.1%.
  • No open-market insider trades in the last 12 months.

3.Financial health

See section β†’
  • Afya Ltd owes $170M more than it holds in cash, about 0.6 years of operating profit.
  • Its return on capital was 16.2%: every 100 invested in the business earned about 16 in a year.
  • Afya Ltd passes 6 of 9 financial health tests (Piotroski F-score).

Afya Ltd in 30 seconds

Good So-so Weak

Good

Are sales growing?

+7.8%

Yes. Sales grew 7.8% last year.

Good

Does it make a profit?

20.4%

Yes. It keeps 20.4% of every sale as profit.

Good

Does profit turn into cash?

36.9%

Yes. 36.9% of sales ends up as free cash.

Good

Is debt under control?

0.6x

Yes. It could repay its debt with 0.6 years of operating profit.

So-so

How healthy are the accounts?

6 / 9

Mixed. It passes 6 of 9 health tests.

For information

How is the share priced?

10.2x

One share costs 10.2 times its yearly profit per share.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$1.4B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
10.2x
On $1.47 EPS (TTM)

Revenue

Total sales reported in the income statement.

KIRA Β· Afya Ltd had $661M of revenue in fiscal 2025, up 7.8% on the year before. Over five years, revenue changed +23.2% a year on average.

See the full section β†’

Operating margin

Operating income as a share of revenue.

KIRA Β· Its operating margin was 32.8%, up 2.2Β pts: of every 100 in sales, about 33 is left after running the business.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Afya Ltd made $135M of net profit in fiscal 2025. From fiscal 2017 to 2025, diluted EPS grew 16.3% a year.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was $244M in fiscal 2025, 36.9% of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

KIRA Β· Its return on capital was 16.2%: every 100 invested in the business earned about 16 in a year.

See the full section β†’

Sales and profit

Is it selling more, and how much does it keep?

Results dates

In plain words: Every quarter, companies publish how much they sold and earned. These are the days Afya Ltd did it, and the next one. Share prices often move a lot on those days.

Next results

November 11, 2026

Wednesday Β· in 16 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
$0.36
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Mar 31, 2026 Period ended Dec 31, 2025 After the market closes 20-F β†—
Apr 29, 2025 Period ended Dec 31, 2024 Time not announced 20-F β†—
Apr 26, 2024 Period ended Dec 31, 2023 After the market closes 20-F β†—
Apr 28, 2023 Period ended Dec 31, 2022 After the market closes 20-F β†—
Apr 29, 2022 Period ended Dec 31, 2021 During market hours 20-F β†—
Apr 30, 2021 Period ended Dec 31, 2020 After the market closes 20-F β†—
Apr 20, 2020 Period ended Dec 31, 2019 After the market closes 20-F β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

Revenue and margins

KIRA Β· Afya Ltd had $661M of revenue in fiscal 2025, up 7.8% on the year before. Over five years, revenue changed +23.2% a year on average. Its operating margin was 32.8%, up 2.2Β pts: of every 100 in sales, about 33 is left after running the business.

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Afya Ltd made $135M of net profit in fiscal 2025. From fiscal 2017 to 2025, diluted EPS grew 16.3% a year.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was $244M in fiscal 2025, 36.9% of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

KIRA Β· Afya Ltd returned $26.3M to shareholders in fiscal 2025, 11% of free cash flow. The diluted share count rose 0.1%.

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· No open-market insider trades in the last 12 months.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

KIRA Β· Afya Ltd owes $170M more than it holds in cash, about 0.6 years of operating profit.

Cash, debt and the ratios that show how comfortably Afya Ltd can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $134M$207M$114M$147M$205M
Debt incl. finance leases $247M$356M$371M$355M$375M
Net debt / EBITDA 1.0x0.9x1.2x0.8x0.6x
Debt / equity 0.5x0.6x0.5x0.5x0.4x
Interest coverage 1.8x1.9x1.7x2.2x2.2x
Current ratio 1.6x1.8x1.1x1.4x2.2x
Quick ratio 1.6x1.8x1.1x1.4x2.2x
Total assets $1.2B$1.4B$1.6B$1.4B$1.7B
Total liabilities $619M$747M$812M$731M$815M
Shareholders' equity $529M$605M$742M$690M$886M
Net debt (βˆ’ = net cash) $112M$149M$257M$208M$170M

Returns on capital

KIRA Β· Its return on capital was 16.2%: every 100 invested in the business earned about 16 in a year.

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

KIRA Β· Afya Ltd passes 6 of 9 financial health tests (Piotroski F-score).

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Cash from operations is positive βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Return on assets rose β€” β€” βœ• βœ“ βœ• βœ“ βœ• βœ“ βœ•
Cash from operations exceeds net income βœ• βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” βœ“ βœ• βœ• βœ• βœ“ βœ• βœ“
Current ratio rose β€” β€” βœ“ βœ• βœ• βœ“ βœ• βœ“ βœ“
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ“ βœ“ βœ• βœ•
Gross margin rose β€” βœ“ βœ“ βœ“ βœ• βœ“ βœ• βœ“ βœ“
Revenue rose relative to assets β€” β€” βœ• βœ• βœ“ βœ“ βœ“ βœ“ βœ•
F-score β€” / 3β€” / 56 / 95 / 94 / 98 / 96 / 97 / 96 / 9
Accruals ratio β€”0.7%βˆ’7.7%βˆ’1.9%βˆ’7.3%βˆ’7.2%βˆ’9.0%βˆ’9.9%βˆ’8.9%
Altman Z'' β€”β€”5.083.402.142.612.342.953.65

All figures

Every number, year by year.

9 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $67.7M $91.3M $190M $233M $319M $451M $576M $613M $661M
Gross profit $28.8M $45.4M $112M $149M $198M $284M $354M $388M $426M
Operating income $15.5M $26.4M $52.0M $70.5M $81.7M $129M $154M $188M $217M
Interest expense $0.3M $0.7M $6.1M $5.0M $45.2M $67.7M $91.6M $85.1M $100M
Pretax income $16.0M $27.0M $47.4M $65.0M $50.7M $82.9M $86.0M $126M $154M
Income tax $0.8M $1.1M $3.6M $5.2M $5.8M $6.9M $4.8M $5.1M β€”
Net income $14.2M $23.6M $39.0M $56.6M $41.4M $72.3M $77.3M $117M $135M
Net income to common $14.2M $23.6M $39.0M $56.6M $41.4M $72.3M $77.3M $117M $135M
Diluted EPS $0.44 $0.50 $0.51 $0.61 $0.44 $0.80 $0.85 $1.29 $1.47
Diluted shares 0.03B 0.05B 0.08B 0.09B 0.09B 0.09B 0.09B 0.09B 0.09B
Cash flow
Cash from operations $12.5M $22.0M $75.8M $72.0M $117M $163M $209M $266M $274M
Capital expenditure $5.3M $5.1M $14.4M $17.4M $23.3M $32.5M $23.7M $25.4M $29.7M
Free cash flow $7.3M $16.9M $61.4M $54.6M $93.6M $131M $185M $240M $244M
Depreciation and amortization $1.3M $2.5M $18.5M $21.1M $28.6M $39.9M $58.0M $61.9M $66.8M
Stock-based compensation β€” $0.6M $4.6M $6.3M $8.0M $6.1M $6.3M $6.0M $2.7M
Dividends paid $0.8M $1.6M $13.1M $2.5M $3.5M $3.8M $3.8M $3.4M $26.3M
Dividends and buybacks $0.8M $1.6M $13.1M $2.5M $3.5M $3.8M $3.8M $3.4M $26.3M
Balance sheet
Cash and short-term investments $7.7M $16.0M $235M $201M $134M $207M $114M $147M $205M
Total debt β€” $20.1M $15.0M $119M $247M $356M $371M $355M $375M
Current assets β€” $34.4M $277M $271M $217M $310M $248M $257M $355M
Current liabilities β€” $47.0M $82.9M $113M $138M $171M $218M $184M $161M
Inventory β€” $0.3M $1.0M $1.4M $2.1M $2.3M $0.3M β€” β€”
Property and equipment, net $19.9M $35.9M $34.7M $50.1M $75.4M $103M $125M $106M $130M
Intangible assets β€” $176M $326M $495M $700M $764M $988M $895M $1.0B
Total assets β€” $237M $725M $923M $1.2B $1.4B $1.6B $1.4B $1.7B
Total liabilities β€” $84.5M $199M $377M $619M $747M $812M $731M $815M
Shareholders' equity $14.1M $129M $514M $536M $529M $605M $742M $690M $886M
Margins
Gross margin 42.6% 49.7% 58.9% 63.8% 62.1% 63.1% 61.4% 63.2% 64.5%
Operating margin 22.8% 28.9% 27.3% 30.2% 25.6% 28.5% 26.7% 30.6% 32.8%
EBITDA margin 24.7% 31.6% 37.1% 39.3% 34.6% 37.4% 36.7% 40.7% 42.9%
Net margin 21.0% 25.9% 20.5% 24.3% 13.0% 16.0% 13.4% 19.1% 20.4%
FCF margin 10.7% 18.5% 32.3% 23.4% 29.4% 29.0% 32.2% 39.2% 36.9%
Returns
Return on capital β€” 19.0% 16.3% 14.3% 11.3% 15.6% 14.5% 20.1% 16.2%
Return on capital employed β€” 13.9% 8.1% 8.7% 8.0% 10.8% 11.4% 15.1% 14.0%
Return on equity 100.8% 32.9% 12.1% 10.8% 7.8% 12.7% 11.5% 16.4% 17.1%
Return on assets β€” 10.0% 8.1% 6.9% 4.0% 5.7% 5.3% 7.8% 8.6%
Return on tangible equity 100.8% β€” 20.8% 140.6% β€” β€” β€” β€” β€”
Growth
Revenue growth β€” 34.9% 108.4% 22.4% 36.8% 41.4% 27.7% 6.5% 7.8%
Net income growth β€” 66.0% 65.2% 45.2% βˆ’26.9% 74.6% 7.0% 51.5% 14.8%
EPS growth β€” 12.0% 3.5% 18.1% βˆ’27.4% 81.5% 7.2% 50.4% 14.6%
FCF growth β€” 132.6% 264.0% βˆ’11.1% 71.4% 39.7% 41.6% 29.8% 1.6%
Share count change β€” 48.4% 59.5% 22.9% 0.5% βˆ’3.7% βˆ’0.1% 0.7% 0.1%
Financial health
Net debt / EBITDA β€” 0.1x βˆ’3.1x βˆ’0.9x 1.0x 0.9x 1.2x 0.8x 0.6x
Debt / equity β€” 0.2x 0.0x 0.2x 0.5x 0.6x 0.5x 0.5x 0.4x
Interest coverage 47.4x 40.1x 8.6x 14.2x 1.8x 1.9x 1.7x 2.2x 2.2x
Current ratio β€” 0.7x 3.3x 2.4x 1.6x 1.8x 1.1x 1.4x 2.2x
Quick ratio β€” 0.7x 3.3x 2.4x 1.6x 1.8x 1.1x 1.4x 2.2x
Capital allocation
Capex / revenue 7.8% 5.6% 7.6% 7.5% 7.3% 7.2% 4.1% 4.1% 4.5%
Stock comp / revenue β€” 0.6% 2.4% 2.7% 2.5% 1.3% 1.1% 1.0% 0.4%
Payouts / FCF 10.8% 9.5% 21.4% 4.6% 3.7% 2.9% 2.0% 1.4% 10.8%
Quality scores
Piotroski F-score β€” β€” 6.0 5.0 4.0 8.0 6.0 7.0 6.0
Altman Z'' β€” β€” 5.1 3.4 2.1 2.6 2.3 3.0 3.7
Accruals ratio β€” 0.7% βˆ’7.7% βˆ’1.9% βˆ’7.3% βˆ’7.2% βˆ’9.0% βˆ’9.9% βˆ’8.9%

Source: SEC EDGAR XBRL filings (CIK 0001771007). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in BRL under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open